Iron plays a critical role in anthracycline-induced cardiotoxicity by disrupting cellular iron homeostasis and interacting with iron regulatory proteins, potentially independent of oxidative stress.
The clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of severe cardiotoxicity. The mechanisms underlying anthracycline-dependent cardiotoxicity are multiple and remain uncompletely understood, but many observations indicate that interactions with cellular iron metabolism are important. Convincing evidence showing that iron plays a role in Doxorubicin cardiotoxicity is provided by the protecting efficacy of iron chelation in patients and experimental models, and studies showing that iron overload exacerbates the cardiotoxic effects of the drug, but the underlying molecular mechanisms remain to be completely characterized. Since anthracyclines generate reactive oxygen species, increased iron-catalyzed formation of free radicals appears an obvious explanation for the aggravating role of iron in Doxorubicin cardiotoxicity, but antioxidants did not offer protection in clinical settings. Moreover, how the interaction between reactive oxygen species and iron damages heart cells exposed to Doxorubicin is still unclear. This review discusses the pathogenic role of the disruption of iron homeostasis in Doxorubicin-mediated cardiotoxicity in the context of current and future pharmacologic approaches to cardioprotection.
Gammella et al. (Wed,) conducted a review in Anthracycline cardiotoxicity. Iron and Anthracyclines was evaluated. Iron plays a critical role in anthracycline-induced cardiotoxicity by disrupting cellular iron homeostasis and interacting with iron regulatory proteins, potentially independent of oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: